Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
Broad coverage extended to Japan and related regions
SAN JOSE, Calif., Jan. 23, 2024 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that its collaborator, Cleveland Clinic, has received a “Decision to Grant” notice from the Japan Patent Office (JPO) for the patent application titled “Ovarian Cancer Vaccines.”
Related news for (ANIX)
- Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences’ Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium
- Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival
- Anixa Biosciences Announces Time Change for Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
- Anixa Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
- Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology